News
US FDA Approves Sun Pharma’s ILUMYA for Active Psoriatic Arthritis
The approval expands the use of the IL-23 inhibitor, previously approved for moderate-to-severe plaque psoriasis, to adults with active psoriatic arthritis.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
The approval expands the use of the IL-23 inhibitor, previously approved for moderate-to-severe plaque psoriasis, to adults with active psoriatic arthritis.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
